

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Antimicrobial prophylaxis in minor and major surgery.

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1504822> since 2017-08-30T17:44:16Z

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

MINERVA ANESTESIOLOGICA
EDIZIONI MINERVA MEDICA

This provisional PDF corresponds to the article as it appeared upon acceptance.
A copyedited and fully formatted version will be made available soon.
The final version may contain major or minor changes.

Antimicrobial prophylaxis in minor and major surgery

Matteo BASSETTI, ELDA RIGHI, AUGUSTA ASTILEAN, S CORCIONE, A
PETROLO, E C FARINA, Francesco Giuseppe DE ROSA

Minerva Anesthesiol 2014 Feb 24 [Epub ahead of print]

MINERVA ANESTESIOLOGICA

Rivista di Anestesia, Rianimazione, Terapia Antalgica e Terapia Intensiva

pISSN 0375-9393 - eISSN 1827-1596

Article type: Review Article

The online version of this article is located at <http://www.minervamedica.it>

Subscription: Information about subscribing to Minerva Medica journals is online at:

<http://www.minervamedica.it/en/how-to-order-journals.php>

Reprints and permissions: For information about reprints and permissions send an email to:

journals.dept@minervamedica.it - journals2.dept@minervamedica.it - journals6.dept@minervamedica.it

Antimicrobial prophylaxis in minor and major surgery.

Bassetti M¹, Righi E¹, Astilean A¹, Corcione S², Petrolo A², Farina EC³, De Rosa FG²

1. Infectious Diseases Division, Santa Maria Misericordia Hospital, Udine, Italy
2. Department of Medical Sciences, Infectious Diseases Clinic, University of Turin, Italy
3. City of Science and Health, Department of General Surgery, Turin, Italy

Key words: *antibiotic prophylaxis, surgical site infection, timing, antimicrobial agent*

Corresponding Author

Matteo Bassetti, MD, PhD

Clinica Malattie Infettive

Azienda Ospedaliera Universitaria Santa Maria della Misericordia

Piazzale Santa Maria della Misericordia 15

33100 Udine

Italy

Phone +39 0432 559355

Fax +39 0432 559360

Email: mattba@tin.it

Abstract

Surgical site infections (SSIs) are a frequent cause of morbidity following surgical procedures. Gram-positive cocci, particularly staphylococci, cause many of these infections, although gram-negative organisms are also frequently involved. The risk of developing a SSI is associated with a number of factors, including aspects of the operative procedure itself, such as wound classification, and patient-related variables, such as preexisting medical conditions. Antimicrobial prophylaxis (AP) plays an important role in reducing SSIs, especially if patient-related risk factors for SSIs are present. The major components of antimicrobial prophylaxis are the timing, the selection of drugs and patients, the duration and the costs. Compliance with these generally accepted preventive principles may lead to overall decreases in the incidence of these infections. Ideally the administration of the prophylactic agent should start within 30 minutes from the surgical incision. The duration of the AP should not exceed 24 hours for the majority of surgical procedures. The shortest effective period of prophylactic antimicrobial administration is not known and studies have demonstrated that post-surgical antibiotic administration is unnecessary. Furthermore, there were no proven benefits in multiple dose regimens when compared to single-dose regimens. The choice of an appropriate prophylactic antimicrobial agent should be based primarily on efficacy and safety. Broad spectrum antibiotics should be avoided due to the risk of promoting bacterial resistance. Cephalosporins are the most commonly used antibiotics in surgical prophylaxis; specifically, cefazolin or cefuroxime are mainly used in the prophylaxis regimens for cardio-thoracic surgery, vascular surgery, hip or knee arthroplasty surgery, neurosurgical procedures and gynaecologic and obstetric procedures. A review of the prophylactic regimens regarding the main surgical procedures is presented.

Introduction

Surgical site infections (SSIs), defined by the Centers for Disease Control (CDC) as infections occurring after surgery in the part of the body where the surgery took place, still represent a major factor of patients' mortality and morbidity (1). Furthermore, health care costs are doubled by SSIs and the length of stay increased by an average of 7 days (1). For these reasons, the importance of perioperative antimicrobial prophylaxis has been well established (1; 2). Antimicrobial prophylaxis (AP) plays an important role in reducing SSIs, especially if patient-related risk factors such as comorbidities (i.e., poor nutritional status, diabetes, immunosuppression), coexistent remote body-site infections, length of preoperative hospitalization, and microbial colonization are present (1)(3).

The special population category represented by obese patients (BMI over 30 kg/m²) has been under-represented in studies and has been shown to have a five-fold higher risk of SSIs compared to non-obese patients; therefore, the choice of an antimicrobial agent and the pharmacokinetic properties in these patients deserve special consideration (4).

AP is efficient in surgical procedures associated with a high rate of infection and in certain clean procedures where the onset of an infection could lead to severe consequences such as prosthetic implants or in cataract surgery (1; 2; 5).

Major components of antimicrobial prophylaxis are represented by the selection, the timing, and the duration of antimicrobials administration (1; 2). Both benefits and the risks should be considered while selecting a prophylactic regimen and the choice should be individualized. The ideal prophylactic antimicrobial agent should prevent SSI-related morbidity and mortality, reduce the duration of hospitalization, have few side effects, and avoid the selection of patients and hospital's resistances. Furthermore, it should be active against the most common pathogens expected to be found at the surgical site and administered at an adequate dosage for the shortest effective period to ensure an efficient serum and tissue concentrations and minimize the adverse effects (1; 2; 5)(3). The route of administration of the prophylactic antimicrobials varies with the type of surgical

procedure. While intravenous administration is overall the preferred route, in selected procedures topical administration (i.e., irrigation, pastes, and washes) was proved to be efficient (1; 2).

Here we reviewed the main notions regarding antimicrobial prophylaxis in surgery, including the pharmacological principles of routinely administered antibiotics (molecule choice, dosing, and timing) and the use of antimicrobial prophylaxis in certain settings (bone cement in orthopedic prosthetic surgery, antibiotic sponges in sternotomy, and antibiotic impregnated shunts in neurosurgery). A review of the studies used in international guidelines regarding the characteristics and recommended regimens of antimicrobial prophylaxis for some of the most discussed specific surgical settings (ocular, neurosurgical, vascular, breast surgery, cesarian section, cholecystectomy, hernias, and surgery of the lower gastrointestinal tract) is also included.

General concepts

Antimicrobial Choice

Recent studies assessing the current practice of prophylaxis throughout the world have shown that over-consumption of antimicrobial drugs, inadequate use of antibiotics and inappropriate timing of administration still remain a remarkable issue in surgical prophylaxis, leading to an increasing risk of adverse effects, hospital costs and emerging resistant microorganisms with associated mortality (1; 6; 7). The selection of the most appropriate antimicrobial agent for prophylaxis in surgical procedures must consider the local resistance patterns along with the SSIs rates at a certain site. Gram-positive cocci, particularly staphylococci, cause many of these infections, although gram-negative organisms are also frequently involved (1) (Table 1). The choice of the antimicrobial should aim to provide: 1. Activity against the common bacteria that might contaminate the surgical site; 2. Adequate serum and tissue concentrations; 3. Safety; 4. Administration for the shortest effective time in order to reduce the side effects, the development of resistance, and the costs (1)(3).

Nevertheless, the choice of an appropriate prophylactic antimicrobial agent should be based primarily on efficacy and safety. Broad spectrum antibiotics should be avoided due to the risk of promoting bacterial resistance. Table 2 reports the recommended doses for different antibiotics used in prophylaxis. Cephalosporins are the most commonly used; specifically, cefazolin or cefuroxime are mainly used in cardio-thoracic surgery, vascular surgery, hip or knee arthroplasty, neurosurgery and gynaecologic procedures (Table 3). History of allergic reactions to beta-lactams should always been investigated in order to prefer alternative regimens in this settings (i.e., vancomycin or clindamycin). Prophylactic regimens in colorectal surgery must associate metronidazole with aminoglycosides or fluoroquinolones as alternatives to beta-lactams in allergic patients. Fluoroquinolones are not recommended as routine prophylactic agents because their extensive use in the past years generated an high rate of resistant strains among enterobacteriaceae (6; 8).

The role of vancomycin in the prophylaxis of surgical procedure is yet to be discussed. In 1995 the CDC developed recommendations for controlling the spread of vancomycin resistance due to the selection of vancomycin-resistant enterococci. Currently, the routine use of vancomycin prophylaxis is not recommended and should be considered only under specific situations (1; 9) (3) (10). Vancomycin prophylaxis is recommended in patients with known or who might be at high risk of methicillin-resistant *Staphylococcus aureus* (MRSA) colonization (i.e., recent hospitalization, contacts with health-care facilities, nursing home residents, haemodialysis patients) undergoing major surgical procedures that involve prosthetic materials or device implantation (9). In patients with documented beta-lactam allergy, the use of prophylactic vancomycin is recommended for gram positive coverage on a case by case basis (1)(3). Due to its long half-life, a single dose of vancomycin administered before surgery is sufficient unless the procedure lasts more than 6 hours, in which case the dose should be repeated. Prophylaxis should be discontinued after a maximum of two doses (1; 2; 9). In a study encompassing 2048 patients undergoing coronary bypass graft or valve replacement surgery receiving vancomycin prophylaxis, the SSIs rate was lowest in the group with a 60 minutes infusion before incision (11; 12). In conclusion, vancomycin prophylaxis should be administered according to the general consideration of the

guidelines but taking in consideration both the resistance patterns of the surgical facility and the patient's characteristics (13).

Antimicrobial administration

Timing and dosing

Ideally, the administration of the prophylactic agent should start within 30 minutes from the surgical incision (2). An exception is represented by fluoroquinolones and vancomycin, that require an infusion starting around 120 minutes before incision due to their long half-lives and in order to prevent antibiotic associated reaction. Duration of the AP should not exceed 24 hours for the majority of surgical procedures (2).

Intraoperative redosing is recommended if the duration of the procedure is longer than two half-lives of the antibiotic agent and/or in case of major blood losses. Although the shortest effective period of AP administration is not known, and studies have demonstrated that post-surgical antibiotic administration is unnecessary. Furthermore, there were no proven benefits in multiple dose regimens when compared to single-dose regimens. Thus, prolonged duration of antimicrobial prophylaxis (up to 48 hours), is no longer recommended by the American Society of Health System Pharmacists (ASHP), even in case of cardiothoracic procedures (1; 6-8; 14).

Topical use of antibiotics in prophylaxis

Local administration of antibiotics is usually preferred to achieve high concentrations in infected tissues and to reduce side effects (15). Not all types of topic administration will be investigated in this paper, but we will focus on the specific use of bone cement in orthopedic prosthetic surgery, antibiotic soaked sponges in sternotomy, and antibiotic impregnated shunts.

Deep wound infection following total joint replacement is not frequent but may represent a devastating complication. In addition to intravenous AP, antibiotic-impregnated bone cement (ABC) has been used replacing the hand-mixed antibiotic preparations. ABC are divided in low-dose ABC (<2.5% of total weight) and high-dose ABC (16). FDA approved ABCs only as a second line treatment for total joint revisions following the removal of the original prosthesis and elimination of active periprosthetic infection. The current guidelines recommendations are controversial; the Scottish Intercollegiate Guidelines Network (SIGN) recommends combined prophylaxis, based on different observational studies which showed a lowest risk of SSI and surgical revisions when AP included the use of ABC (17-19). The Italian National Guidelines System (SNLG) recommends intravenous prophylaxis and the UK National Institute for Health and Clinical Excellence (NICE) guidelines do not consider the issue. Finally, the American Society of Health-System Pharmacists (ASHP) does not recommend AP routinely because of the lack of a significant advantage. Nevertheless, the ASHP recommendation did not consider two studies and a meta-analysis displaying a significant reduction using ABC versus standard prophylaxis of deep SSIs (1.2 % versus 2.3%; OR=0.5; CI 95% 0.34-0.75) and surgical revision (3.1% versus 4%; OR=0.72; CI 95% 0.62-0.82) in high-risk patients (i.e., diabetics) (20-22). In conclusion, the effectiveness of ABC is not clearly demonstrated and it is not routinely recommended, although its use may be useful in revision surgery and in high risk patients (16).

Sternal wound infections and mediastinitis are uncommon but serious complications of thoracotomy; the incidence of mediastinitis ranges from 1% to 5% and the mortality rate can be as high as 30% (23-25). Use of local antibiotic, usually gentamicin, could reduce this infection. The SIGN guidelines considered a first study based on 542 patients showing a non-statistically significant reduction of SSIs and mediastinitis (26), while the second study reported a significant decrease of mediastinitis and SSIs in high risk patients (27). The SNLG guidelines did not consider this issue and the NICE guidelines cited two studies and a meta-analysis that showed a reduction of infection (OR=0.49, CI 95% 0.34-0.60). The effectiveness of antibiotic sponges as prophylaxis is uncertain and may be considered in high risk patients.

Antibiotic-impregnated shunts are used along with intravenous prophylaxis in neurosurgery to reduce infection of cerebrospinal fluid (CSF) in shunts or external ventricular drainage devices (28; 29). The SIGN guidelines are based on an experimental study and three trials, showing a reduction of bacterial colonization of catheters (from 37% to 18%) and positive CSF cultures (from 9% to 1%) (30-32); accordingly, AP is recommended where a high incidence of infection is documented. The SNLG and NICE guidelines did not give any recommendations on the issue while the ASHP guidelines highlighted that many neurosurgeons did not use antibiotic-impregnated shunts (33). To date, the effectiveness of antibiotic-impregnated shunts is uncertain and cannot yet be recommended.

Antimicrobial prophylaxis in different clinical settings

Ocular surgery

The antimicrobial prophylaxis in ophthalmological surgery is aimed mainly against a rare, yet severe postoperative complication: the acute infectious endophthalmitis. Most of the data published involved mainly cataract procedures. The reported incidence of this complication after cataract procedures is low, approximately 0.082%, but the severity of endophthalmitis justifies the need for prophylaxis (1; 34; 35). The microorganisms responsible originate from the normal bacterial flora of the patient's eyelid and conjunctiva and in 25% to 60 % of cases are represented by coagulase-negative *Staphylococcus* species and, less frequently, by Gram negative microorganisms as reported in Table 1 (1; 5; 34; 35). The risk factors for developing ophthalmic infections are diabetes, lacrimal drainage system infection and/or obstruction, and immunodeficiency (3) (34; 35). Due to the low rate of endophthalmitis, data regarding the efficacy of antibiotic prophylaxis is limited [16]. Ideally, the antimicrobial prophylactic agent should be effective against the common periocular flora, and safe intraocular administration. Site preparation and disinfection with antiseptic solution such as povidone-iodine 5% and 10% solution and chlorhexidine solution are mandatory (5; 35-37). Prophylactic regimens include cephalosporins

(especially cefazolin, cefuroxime and ceftazidime), vancomycin, and aminoglycosides combined with antiseptic solutions (1; 37; 38). Fluoroquinolones have been proved to have significant efficacy against common ocular pathogens with improved intraocular penetration, particularly moxifloxacin (5; 34; 35; 39-41)(42). The most efficient route of administration is still debated due to the lack of well-controlled studies. To date, preoperative topical antimicrobial drops, antimicrobial irrigation solution, subconjunctival injection of antimicrobial, and postoperative topical irrigation are equally effective (1; 34-36). The duration and timing reported in the literature ranged from one to multiple droplets administered combined pre-, peri-, intra- and post-operative, but the data provided is still insufficient.

Neurosurgery

Nosocomial central nervous system (CNS) infections have low incidence rates but pose serious consequences. *Narotam et al.* classified the neurosurgical procedures in clean, clean with a foreign body, clean contaminated, contaminated, and dirty (43). Clean procedures in neurosurgery include elective craniotomy, spinal procedures, laminectomy; foreign body clean procedures include *in situ* devices (e.g. shunt, intracranial pressure monitors, clamps, external ventricular drains, acrylic cranioplasties and metal rods). Postoperative CNS infections include meningitis, ventriculitis, cerebrospinal fluid (CSF) infection, and less frequently, SSIs. Overall, the reported incidence of postoperative infections in clean procedures (primarily craniotomy) ranges from 0.15% to 6.1% with antimicrobial prophylaxis (44). Risk factors for postoperative neurosurgical infections are: American Society of Anaesthesiologists (ASA) classification > 2, postsurgical monitoring of intracranial pressure or ventricular drains implant for more than 5 days, cerebrospinal fluid (CSF) leakage, prolonged (> 2 hours) surgical procedure, reintervention, concurrent (remote, incision or shunt) infection, diabetes, and emergency procedures. The majority of neurosurgical site infections and other postoperative infections typically occur within two weeks to one month of the procedure (1; 33; 43-46). The organisms that are most frequently implicated are reported in Table 1. Gram negative bacteria are rarely implicated and, in this case, the infection is usually polymicrobial (1; 43; 44).

Antibiotic prophylaxis is recommended in clean procedures and antimicrobial agents usually used are represented by cephalosporins (table 3). Other antimicrobials such as clindamycin, vancomycin, cefotiam (currently not available in the United States), cloxacillin, oxacillin, cefuroxime, trimethoprim-sulfamethoxazole, cefazolin, penicillin G, and amoxicillin-clavulanate proved to have similar efficacy in various studies (32; 46-49). The recommended timing of the prophylaxis administration is within 60 minutes before surgical incision and a single dose of antibiotic is generally efficient (1; 44)(3). Antibiotic prophylaxes for CSF-shunting procedures have proven beneficial in reducing the infection rates but the issue is still open for discussion. Routinely use of impregnated devices in neurosurgery is not recommended but may be considered under special circumstances, especially if the local CSF infection rates are high (1; 32; 44). Studies compared antimicrobial-impregnated shunts to standard non-microbial impregnated shunts in patients undergoing antibiotic prophylaxis before the procedure showing no significant decrease of infection rates between the two groups (48; 49). No significant reduction of the risk of infection was demonstrated with prolonged prophylaxis administration (33; 45).

Vascular surgery

SSI are a rather rare complication following vascular surgery but are associated to a high rate of morbidity and mortality. Antimicrobial prophylaxis is widely used and especially in procedures involving implantation of graft material and procedures at risk of developing infection, such as vein bypass and thrombendarrectomy (1; 50; 51). Surgical procedures with no prosthetic material implantation, such as brachial artery repair or carotid endarterectomy do not appear to benefit from antimicrobial prophylaxis. Routine prophylaxis is recommended for: endograft placement, aortic and superficial femoral artery recanalization, dialysis accesses, embolization and chemoembolization angiography, angioplasty, thrombolysis, arterial closure device placement, and central venous access in immunocompromised patients. Furthermore, prophylaxis should be considered in patients with long surgical time (≥ 2 hours), reintervention on site within the first week, vascular stent implementation in the inguinal canal, immunosuppression, and history of prosthetic surgery (3)(1; 52). The bacterial flora implicated is mainly

represented by Gram positive as reported in Table 1 (53). MRSA colonization is an important, independent factor associated to higher risk of post-procedural complications (50; 51; 54). As reported in Table 4, cefazolin remains the antimicrobial agent recommended (55-58). Alternative recommended prophylactic agents in patients with beta-lactams allergies are clindamycin, vancomycin, fluoroquinolones or aztreonam (1; 50; 51). If gram negative bacteria are a concern, a single dose of aminoglycosides or fluoroquinolones should be used. Intranasal mupirocin should be considered for staphylococcal nasal decolonization. The timing of administration should be within one hour before skin incision, with a single dose and for a maximum of 24 hour postoperatively (50).

Breast surgery

Breast surgery is heterogeneous because of type of treatment (needle biopsy, lumpectomy, and mastectomy), cause of surgery (tumour or plastic procedure) and presence of prosthesis. The incidence of SSIs ranges from 1% to 30% with a prevalence of gram negative bacteria (40-50%) (59; 60). A higher incidence is reported in mastectomies (61-63), in early reconstruction after mastectomy, chemotherapy, and / or local radiotherapy, in presence of implants, expanders or drainage and in reoperations (64-69). A lower incidence is reported in needle biopsies (70). The most recent American report of NHSN showed SSI rates ranging from 0.9% to 6.4% (71); European reports showed rates from 0.5-% and 4% (165-167). In 2007, AP was reported from European studies in 60-80% of mammoplasties and in 30% of mastectomies (70) and more frequently in reports from the US especially in presence of prosthesis and drainage (90%) (72). Recommendations regarding antimicrobial prophylaxis in breast surgery are controversial. SIGN guidelines do not suggest AP (73; 74), but a meta-analysis of Cochrane showed SSI reduction in oncological surgery (66). SNLG recommend AP in oncological surgery and reductive mammoplasty. NICE guidelines recommend AP in oncological surgery but not in reconstructive surgery (with or without prosthesis) (75)[139]. ASHP guidelines recommended AP in oncological surgery based on a metanalysis and retrospective studies (76-80). All these guidelines did not consider two recent metaanalysis that confirmed a reduction of SSI in patients undergoing AP (6.5% versus 9.3%, respectively) (81; 82). The type of

antimicrobial suggested is reported in table 4. Regarding the timing of prophylaxis administration, a retrospective study regarding reduction mammoplasty reported that the incidence of SSIs had increased when AP was administered for only 24 h but other three retrospective studies had different results (83-85). Finally, a review demonstrated that the extension of AP did not change incidence of SSIs (86). Similar results were showed in oncologic surgery (87). Despite these conclusions, American surgeons tend to extend the duration of AP (72). So far, according to available data, the evidence is still unclear. However, considering the reliability of meta-analysis we suggest the use of AP in all breast surgery, with the exception of needle biopsy.

Cholecystectomy

Open cholecystectomy is classified as a clean/contaminated procedure involving the gastrointestinal tract without major contamination or inflammation (CDC Surgical Wound Classification, class II) (88). Laparoscopic cholecystectomy has become the gold standard treatment for symptomatic cholelithiasis over open cholecystectomy (89; 90). AP has been always recommended by the available guidelines in open cholecystectomy, whilst in laparoscopic cholecystectomy is still controversial because of the lower incidence of SSI (91-93). Before the introduction of AP the incidence of SSI was 10-20% (94). Data from recent US and European studies reported rates ranging from 0.2% to 1.7% and 0.4% to 6.8%, respectively (71)(165,166). Risk factors associated with an increased incidence of SSI (> 25%) in laparoscopic cholecystectomy include: emergency surgery, age >70, ASA \geq 3, biliary colic in the last 30 days, jaundice, pregnancy, immunosuppression, diabetes, endoscopic or percutaneous drainage, acute cholecystitis, gallbladder exclusion, lithiasis, pancreatitis, intraoperative cholangiography, duration of surgery >2 hours, and intraoperative complications (1)(3)(89; 95). A review of available guidelines showed that SIGN guidelines, based on a meta-analysis published in 2004, did not suggest AP in laparoscopic cholecystectomy along with the NICE and SNLG guidelines which were based on the same meta-analysis and two additional reviews (96-98). The ASHP guidelines also included an observational study, which showed a lower incidence of SSI with AP (both in open cholecystectomy than in laparoscopic

cholecystectomy) (99) and two meta-analysis that did not confirm the efficacy of AP in low-risk patients (100; 101). A study where antibiotics were given after accidental perforation of the gallbladder during laparoscopic cholecystectomy did not change the incidence of SSI (2.5% versus 3.4%) (102). However, UK surveillance studies reported that 80% of patients undergoing laparoscopic cholecystectomy (103) received AP and a recent European study highlighted that 70% of hospital guidelines recommended AP only in high risk patients and 10% of guidelines recommended in all cases of laparoscopic cholecystectomy (104). The heterogeneity in recommendations may be based on the frequent exclusion of high risk patients from trials and limited number of patients enrolled. Given the low incidence of SSIs, a significant result would require randomized controlled trials with at least 1000 patients (94; 105). Furthermore, all trials are not based on the “intention-to-treat” method and results are calculated only with low risk patients. In conclusion, AP is mandatory in open cholecystectomy, while in laparoscopic cholecystectomy is recommended only in selected patients but there are no indications on low risk patients with complications during surgery. Preferred antimicrobial regimen is indicated in table 4.

Cesarean section

The efficacy of AP during cesarean section is well known (1; 41)(106); a recent Cochrane metanalysis, based on 86 studies with 13,000 patients showed a reduction of endometritis (OR 0.38; CI 95% 0.34-0.48) as well as SSI (OR 0.39; CI 95% 0.32-0.48)] with AP. A Cochrane review reported an incidence of 10% for wound infection and of 17% for EN in absence of AP (165). The most recent American report of NHSN showed values from 1.5% (RI=0) to 3.8% (RI=2-3) (71); European reports showed rates from 0.7-2.7% (RI=0) to 0.7- 4.5% (RI=3) (165-167). Timing of AP administration is still controversial. Since 2000, AP was recommended after clamping the cord (107; 108)(109)(110) to prevent that antibiotic could reach the newborn causing an increased risk of flora alteration, selection of resistant bacteria, neonatal sepsis and increased susceptibility to asthma (111). In the last decade several studies showed a higher efficacy of AP during cesarean section if compared to AP after cord clamping and no data confirmed the above mentioned side effects in neonates. Thus, currently AP after

cord clamping administration is not recommended. SIGN guidelines and NICE guidelines agreed on antibiotic administration before or after cordon clamp (112). ASHP guidelines strongly suggested preoperative AP (113). A meta-analysis on three trials with 749 patients described a significantly reduction of endometritis (OR 0.47; CI 95% 0.26-0.85) and wound infections from 5.4 to 3.1% (OR 0.60 – CI 95% 0.30-1.21) (114). Data from recent literature agreed on efficacy of preoperative AP to reduce endometritis (OR between 0.48 and 0.59), whilst data are controversial about wound infections reduction: three metanalysis confirmed a decrease of wound infections, while one described a slight insignificant increase of infections (113; 115-126)(127). One retrospective study, based on 4229 patients in US, reported a lower incidence of both EN and wound infections (2.2% vs. 3.9% and 2.5 % vs. 3.6%, respectively) (118). In conclusion, in the last decade data showed that preoperative AP administration is more effective than AP after cord clamping to reduce EN and even if with less efficacy, to reduce wound infections; moreover it does not cause side effects on newborns and it is therefore recommended. Table 4 reports evidence for recommended regimens.

Urological surgery

The purpose of antimicrobial prophylaxis in urological surgery procedures is to prevent bacteriemia, post-operative bacteriuria, SSI and nosocomial urinary tract infections (UTI), which are a common cause of patients' mortality and morbidity and increase the costs of hospitalization (8). Although the efficacy of antimicrobial prophylaxis in preventing post-operative complications has been established, surveys have shown that inadequate selection of agents, improper timing and/or duration of prophylaxis may interfere with the benefits (1; 128; 129). In addition to the general risk factors of the patient there are specific urologic risk factors that need to be considered: indwelling catheter, previous urogenital infection and long preoperative hospitalization (128; 130). The most common organisms isolated postoperative are reported in Table 1. Biofilm-forming bacteria are also of concern, therefore the antibiotics selected for prophylaxis must cover the expected microorganisms and should take into account the local resistance patterns (1; 8; 128)(3). The duration of antimicrobial prophylaxis therapy should be single dose or less than 24 hours (1; 129; 130)(3). No antimicrobial agent has proven to be

superior for urologic procedures and various regimens have been evaluated including cephalosporins, fluoroquinolones, aminoglycosides, nitrofurantoin and trimethoprim-sulfamethoxazole (131-133). The efficacy of fluoroquinolones has been well established, but the recent high fluoroquinolones bacterial resistance should be taken into consideration. Broad spectrum antibiotics such as third generation cephalosporins, carbapenems or glycopeptides are not recommended and due to their high costs, similar efficacy and the potential to promote resistance should be reserved for patients with active infections (134-137). Patients with preoperative bacteriuria or UTI should be treated before the procedure. For patients undergoing clean urologic procedures cefazolin is recommended with the alternative of fluoroquinolone or a combination of an aminoglycoside plus metronidazole (138). In patients with penicillin allergy, vancomycin or clindamycin are recommended (1; 129; 130)(3). For clean-contaminated procedures the antibiotic regimen should include a combination of cefazolin with or without metronidazole, cefoxitin, fluoroquinolone, trimethoprim-sulfamethoxazole or aminoglycoside combined with metronidazole or clindamycin (1; 8; 129; 138; 139). Surgical antimicrobial prophylaxis is recommended only if the potential benefits exceed the risks and anticipated costs.

Hernia

Inguinal hernia is a very common problem and surgical repair is the current approach. Inguinal hernia repair is classified as clean surgery and AP is not recommended since SSI following hernia repair are usually superficial and they successfully treated with drainage. Since the 90s, with the introduction of prosthetic materials, some authors supported AP and experimental studies prophylaxis showed a reduction of infection after placement of propylene mesh (140-142). So far, there is no data showing an higher incidence of SSIs in hernioplasty (EP) compared to herniorrhaphy (repair without prosthetic material) (143). The incidence of SSI in this procedure is < 2% (73; 144; 145), but several studies reported an average incidence ranging from 4% to 10% (146)(147; 148). The most recent US and European studies showed incidence between 0.7% to 5.2% and from 0.3 % to 5.3%, respectively (165-167). A lower incidence of SSIs is described for laparoscopic hernia repair (149-151). However, recent studies confirmed a protective effect of AP in preventing SSI: a surveillance study conducted in

Italy and Spain showed that 50% of surgeons used AP in hernia repair (52; 152) while in the UK AP was used by 90% of surgeons (153). Recommended regimens are displayed in table 4. It should be stated that all these studies included a low number of patients, differences in dosages, time of infusion and way of antibiotics administration, without data about patients' risk factors, useful to identify patients in which AP should be effective. In conclusion, according to recent meta-analyses, AP in EP is recommended while in ER it should be considered, especially in hospitals with high incidence of SSIs. In some groups of patients, with low risk of SSIs, AP can be omitted, but the definitions of these patients remain unclear. For laparoscopic surgery and incisional hernia there are no studies available: some experts suggest to use AP according to same principles as in traditional technique.

Colorectal surgery

The effectiveness of AP is well documented in literature as it decreases the incidence of SSI from 30-60% (154; 155) to 5-15% (156) and mortality from 10% to 2-4% (157). There is a higher rate of SSIs in rectal resection compared to colic resection (158-160). Laparoscopic surgery seems to be associated with a lower incidence of SSI (161-163), especially for SSIs of incisional site (164). The most recent US study of NHSN describes an incidence of SSIs for colic resection ranging from 4% to 9% and for rectal resection from 3.5% to 26% (71) while, according to European reports, the incidence is between 3.9 - 6.6% and 11.5 - 16.8% (165)(166)(167). There are differences between US and European studies. In the US, oral AP was usually preferred (168; 169) with an association of aminoglycoside (neomycin or kanamycin) and an effective antibiotic against aerobic microorganisms (170-174). Combination of neomycin and erythromycin seems to be most effective compared to metronidazole monotherapy (175). There is no data of effectiveness of oral AP in colon surgery without mechanical bowel preparation (MBP) since, according to experimental models, MBP alone does not change intraluminal bacterial contamination (176) while MBP associated with oral AP reduce bacterial counts by a factor of 10^5 (177). Moreover, a recent retrospective study showed that oral AP is effective irrespectively of MBP

(178), but the question is still debated (179)(180)(181-190). Oral AP has been associated with an increased incidence of postoperative diarrhoea or *Clostridium difficile* infection (191), but this effect was not confirmed by others (192). Conversely, in Europe intravenous AP is usually preferred; its effectiveness was demonstrated in 1960 (193) with several studies with antibiotics effective on both aerobic and anaerobic bacteria (194; 195). The comparison between oral and intravenous AP is difficult (196; 197), also considering the recommendations of the existing guidelines. According to SIGN, SNLG and NICE guidelines, only intravenous administration was included while ASHP guidelines considered extensively oral AP, evaluating a combined administration (oral plus intravenous) versus systemic antibiotics alone (198; 199), as well as combined AP versus oral administration alone. In most cases, ASHP guidelines recommended combined prophylaxis. However, it should be specified that data from literature are highly heterogeneous because of the use of oral or intravenous AP, choice of the molecules, timing and length of administration. For example, not all studies considered as standard oral prophylaxis the administration of neomycin 1 gr plus erythromycin 1gr three times a day (169; 200-202). Nowadays, comorbidities, type of surgical procedure, surgical demolition and bacterial contamination are variables that should be considered (203). In conclusion, effectiveness of AP in colorectal surgery is certainly demonstrated. As reported in table 4, the ASHP guidelines support the use of oral plus intravenous AP while the utility of MBP is unclear.

Key messages

- Antimicrobial prophylaxis (AP) plays an important role in reducing SSIs, especially if patient-related risk factors for SSIs are present
- The administration of the prophylactic agent should start within 30 minutes from the surgical incision.
- The choice of the antimicrobial should aim to provide: 1. Activity against the common bacteria that contaminate the surgical site; 2. Adequate serum and tissue concentrations; 3. Safety; 4. Administration for the shortest effective time in order to reduce the side effects, the development of resistance, and the costs

- Cefazolin remains the antimicrobial agent recommended for the majority of surgical procedures. Alternative recommended prophylactic agents in patients with beta-lactams allergies are clindamycin, vancomycin, fluoroquinolones or aztreonam
- Duration of antimicrobial prophylaxis should not exceed 24 hours for the majority of surgical procedures

References

1. Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, et al. 2013. Clinical practice guidelines for antimicrobial prophylaxis in surgery. *American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists* 70:195-283
2. Weber WP, Marti WR, Zwahlen M, Misteli H, Rosenthal R, et al. 2008. The timing of surgical antimicrobial prophylaxis. *Annals of surgery* 247:918-26
3. Scottish Intercollegiate Guidelines Network. SIGN. Antibiotic prophylaxis in surgery. A national clinical guideline. July 2008
4. Waisbren E, Rosen H, Bader AM, Lipsitz SR, Rogers SO, Jr., Eriksson E. 2010. Percent body fat and prediction of surgical site infection. *Journal of the American College of Surgeons* 210:381-9
5. Ta CN, Egbert PR, Singh K, Shriver EM, Blumenkranz MS, Mino De Kaspar H. 2002. Prospective randomized comparison of 3-day versus 1-hour preoperative ofloxacin prophylaxis for cataract surgery. *Ophthalmology* 109:2036-40; discussion 40-1
6. Bratzler DW, Houck PM, Surgical Infection Prevention Guideline Writers W. 2005. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. *American journal of surgery* 189:395-404
7. Al-Azzam SI, Alzoubi KH, Mhaidat NM, Haddadin RD, Masadeh MM, et al. 2012. Preoperative antibiotic prophylaxis practice and guideline adherence in Jordan: a multi-centre study in Jordanian hospitals. *Journal of infection in developing countries* 6:715-20
8. Bratzler DW, Houck PM, Richards C, Steele L, Dellinger EP, et al. 2005. Use of antimicrobial prophylaxis for major surgery: baseline results from the National Surgical Infection Prevention Project. *Archives of surgery* 140:174-82
9. Gould IM. 2009. Comment on: Interventions to control MRSA: high time for time-series analysis? *The Journal of antimicrobial chemotherapy* 63:224
10. Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). <http://www.cdc.gov/mmwr/PDF/RR/RR4412.PDF>
11. Cotogni P, Passera R, Barbero C, Gariboldi A, Moscato D, et al. 2013. Intraoperative vancomycin pharmacokinetics in cardiac surgery with or without cardiopulmonary bypass. *The Annals of pharmacotherapy* 47:455-63
12. Garey KW, Dao T, Chen H, Amrutkar P, Kumar N, et al. 2006. Timing of vancomycin prophylaxis for cardiac surgery patients and the risk of surgical site infections. *The Journal of antimicrobial chemotherapy* 58:645-50
13. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. 1999. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. *Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America* 20:250-78; quiz 79-80
14. van Kasteren ME, Kullberg BJ, de Boer AS, Mintjes-de Groot J, Gyssens IC. 2003. Adherence to local hospital guidelines for surgical antimicrobial prophylaxis: a multicentre audit in Dutch hospitals. *The Journal of antimicrobial chemotherapy* 51:1389-96
15. Huiras P, Logan JK, Papadopoulos S, Whitney D. 2012. Local antimicrobial administration for prophylaxis of surgical site infections. *Pharmacotherapy* 32:1006-19
16. Jiranek W. 2005. Antibiotic-loaded cement in total hip replacement: current indications, efficacy, and complications. *Orthopedics* 28:s873-7
17. Engesaeter LB, Lie SA, Espehaug B, Furnes O, Vollset SE, Havelin LI. 2003. Antibiotic prophylaxis in total hip arthroplasty: effects of antibiotic prophylaxis systemically and in bone cement on the revision rate of 22,170 primary hip replacements followed 0-14 years in the Norwegian Arthroplasty Register. *Acta orthopaedica Scandinavica* 74:644-51
18. Espehaug B, Engesaeter LB, Vollset SE, Havelin LI, Langeland N. 1997. Antibiotic prophylaxis in total hip arthroplasty. Review of 10,905 primary cemented total hip replacements reported to the Norwegian arthroplasty register, 1987 to 1995. *The Journal of bone and joint surgery. British volume* 79:590-5
19. Engesaeter LB, Espehaug B, Lie SA, Furnes O, Havelin LI. 2006. Does cement increase the risk of infection in primary total hip arthroplasty? Revision rates in 56,275 cemented and uncemented primary THAs followed for 0-16 years in the Norwegian Arthroplasty Register. *Acta orthopaedica* 77:351-8
20. Parvizi J, Saleh KJ, Ragland PS, Pour AE, Mont MA. 2008. Efficacy of antibiotic-impregnated cement in total hip replacement. *Acta orthopaedica* 79:335-41

21. Chiu FY, Lin CF, Chen CM, Lo WH, Chaung TY. 2001. Cefuroxime-impregnated cement at primary total knee arthroplasty in diabetes mellitus. A prospective, randomised study. *The Journal of bone and joint surgery. British volume* 83:691-5
22. Chiu FY, Chen CM, Lin CF, Lo WH. 2002. Cefuroxime-impregnated cement in primary total knee arthroplasty: a prospective, randomized study of three hundred and forty knees. *The Journal of bone and joint surgery. American volume* 84-A:759-62
23. Friberg O, Svedjeholm R, Kallman J, Soderquist B. 2007. Incidence, microbiological findings, and clinical presentation of sternal wound infections after cardiac surgery with and without local gentamicin prophylaxis. *European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology* 26:91-7
24. Higgins TL, Estafanous FG, Loop FD, Beck GJ, Blum JM, Paranandi L. 1992. Stratification of morbidity and mortality outcome by preoperative risk factors in coronary artery bypass patients. A clinical severity score. *JAMA : the journal of the American Medical Association* 267:2344-8
25. Valla J, Corbineau H, Langanay T, Sevray B, Felix C, et al. 1996. [Mediastinitis after cardiac surgery. A 10-year evaluation (1985-1995)]. *Annales de cardiologie et d'angeiologie* 45:369-76
26. Eklund AM, Valtonen M, Werkkala KA. 2005. Prophylaxis of sternal wound infections with gentamicin-collagen implant: randomized controlled study in cardiac surgery. *The Journal of hospital infection* 59:108-12
27. Friberg O, Dahlin LG, Levin LA, Magnusson A, Granfeldt H, et al. 2006. Cost effectiveness of local collagen-gentamicin as prophylaxis for sternal wound infections in different risk groups. *Scandinavian cardiovascular journal : SCJ* 40:117-25
28. Bayston R, Ashraf W, Fisher L. 2007. Prevention of infection in neurosurgery: role of "antimicrobial" catheters. *The Journal of hospital infection* 65 Suppl 2:39-42
29. Lietard C, Thebaud V, Besson G, Lejeune B. 2008. Risk factors for neurosurgical site infections: an 18-month prospective survey. *Journal of neurosurgery* 109:729-34
30. Zabramski JM, Whiting D, Darouiche RO, Horner TG, Olson J, et al. 2003. Efficacy of antimicrobial-impregnated external ventricular drain catheters: a prospective, randomized, controlled trial. *Journal of neurosurgery* 98:725-30
31. Sciubba DM, Stuart RM, McGirt MJ, Woodworth GF, Samdani A, et al. 2005. Effect of antibiotic-impregnated shunt catheters in decreasing the incidence of shunt infection in the treatment of hydrocephalus. *Journal of neurosurgery* 103:131-6
32. Aryan HE, Meltzer HS, Park MS, Bennett RL, Jandial R, Levy ML. 2005. Initial experience with antibiotic-impregnated silicone catheters for shunting of cerebrospinal fluid in children. *Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery* 21:56-61
33. McCarthy PJ, Patil S, Conrad SA, Scott LK. 2010. International and specialty trends in the use of prophylactic antibiotics to prevent infectious complications after insertion of external ventricular drainage devices. *Neurocritical care* 12:220-4
34. Gore DM, Angunawela RI, Little BC. 2009. United Kingdom survey of antibiotic prophylaxis practice after publication of the ESCRS Endophthalmitis Study. *Journal of cataract and refractive surgery* 35:770-3
35. Gordon-Bennett P, Karas A, Flanagan D, Stephenson C, Hingorani M. 2008. A survey of measures used for the prevention of postoperative endophthalmitis after cataract surgery in the United Kingdom. *Eye* 22:620-7
36. Hariprasad SM, Blinder KJ, Shah GK, Apte RS, Rosenblatt B, et al. 2005. Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous. *Archives of ophthalmology* 123:39-44
37. Montan PG, Wejde G, Setterquist H, Rylander M, Zetterstrom C. 2002. Prophylactic intracameral cefuroxime. Evaluation of safety and kinetics in cataract surgery. *Journal of cataract and refractive surgery* 28:982-7
38. Cahane M, Ben Simon GJ, Barequet IS, Grinbaum A, Diamanstein-Weiss L, et al. 2004. Human corneal stromal tissue concentration after consecutive doses of topically applied 3.3% vancomycin. *The British journal of ophthalmology* 88:22-4
39. Holland EJ, McCarthy M, Holland S. 2007. The ocular penetration of levofloxacin 1.5% and gatifloxacin 0.3% ophthalmic solutions in subjects undergoing corneal transplant surgery. *Current medical research and opinion* 23:2955-60
40. Montan PG, Setterquist H, Marcusson E, Rylander M, Ransjo U. 2000. Preoperative gentamicin eye drops and chlorhexidine solution in cataract surgery. Experimental and clinical results. *European journal of ophthalmology* 10:286-92

41. Garcia-Saenz MC, Arias-Puente A, Fresnadillo-Martinez MJ, Carrasco-Font C. 2001. Human aqueous humor levels of oral ciprofloxacin, levofloxacin, and moxifloxacin. *Journal of cataract and refractive surgery* 27:1969-74
42. Frank A, Bucci Jr; An in vivo study comparing the ocular absorption of levofloxacin and ciprofloxacin prior to phacoemulsification; *Am J Ophthalmol.* 2004 Feb;137(2):308-12
43. Narotam PK, van Dellen JR, du Trevo MD, Gouws E. 1994. Operative sepsis in neurosurgery: a method of classifying surgical cases. *Neurosurgery* 34:409-15; discussion 15-6
44. Rebuck JA, Murry KR, Rhoney DH, Michael DB, Coplin WM. 2000. Infection related to intracranial pressure monitors in adults: analysis of risk factors and antibiotic prophylaxis. *Journal of neurology, neurosurgery, and psychiatry* 69:381-4
45. Korinek AM, Golmard JL, Elcheick A, Bismuth R, van Effenterre R, et al. 2005. Risk factors for neurosurgical site infections after craniotomy: a critical reappraisal of antibiotic prophylaxis on 4,578 patients. *British journal of neurosurgery* 19:155-62
46. Ragel BT, Browd SR, Schmidt RH. 2006. Surgical shunt infection: significant reduction when using intraventricular and systemic antibiotic agents. *Journal of neurosurgery* 105:242-7
47. Arnaboldi L. 1996. Antimicrobial prophylaxis with ceftriaxone in neurosurgical procedures. A prospective study of 100 patients undergoing shunt operations. *Chemotherapy* 42:384-90
48. Govender ST, Nathoo N, van Dellen JR. 2003. Evaluation of an antibiotic-impregnated shunt system for the treatment of hydrocephalus. *Journal of neurosurgery* 99:831-9
49. Ratilal B, Costa J, Sampaio C. 2008. Antibiotic prophylaxis for surgical introduction of intracranial ventricular shunts: a systematic review. *Journal of neurosurgery. Pediatrics* 1:48-56
50. Venkatesan AM, Kundu S, Sacks D, Wallace MJ, Wojak JC, et al. 2010. Practice guidelines for adult antibiotic prophylaxis during vascular and interventional radiology procedures. Written by the Standards of Practice Committee for the Society of Interventional Radiology and Endorsed by the Cardiovascular Interventional Radiological Society of Europe and Canadian Interventional Radiology Association [corrected]. *Journal of vascular and interventional radiology : JVIR* 21:1611-30; quiz 31
51. Engelman R, Shahian D, Shemin R, Guy TS, Bratzler D, et al. 2007. The Society of Thoracic Surgeons practice guideline series: Antibiotic prophylaxis in cardiac surgery, part II: Antibiotic choice. *The Annals of thoracic surgery* 83:1569-76
52. Mozzillo N, Greco D, Pescini A, Formato A. 1988. Chemoprophylaxis in the surgical ward: results of a national survey in Italy. *European journal of epidemiology* 4:357-9
53. Cantlon CA, Stemper ME, Schwan WR, Hoffman MA, Qutaishat SS. 2006. Significant pathogens isolated from surgical site infections at a community hospital in the Midwest. *American journal of infection control* 34:526-9
54. Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, et al. 2013. Clinical practice guidelines for antimicrobial prophylaxis in surgery. *Surgical infections* 14:73-156
55. Bolon MK, Morlote M, Weber SG, Koplan B, Carmeli Y, Wright SB. 2004. Glycopeptides are no more effective than beta-lactam agents for prevention of surgical site infection after cardiac surgery: a meta-analysis. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 38:1357-63
56. Finkelstein R, Rabino G, Mashiah T, Bar-El Y, Adler Z, et al. 2002. Vancomycin versus cefazolin prophylaxis for cardiac surgery in the setting of a high prevalence of methicillin-resistant staphylococcal infections. *The Journal of thoracic and cardiovascular surgery* 123:326-32
57. Maki DG, Bohn MJ, Stolz SM, Kroncke GM, Acher CW, Myerowitz PD. 1992. Comparative study of cefazolin, cefamandole, and vancomycin for surgical prophylaxis in cardiac and vascular operations. A double-blind randomized trial. *The Journal of thoracic and cardiovascular surgery* 104:1423-34
58. Marroni M, Cao P, Fiorio M, Maghini M, Lenti M, et al. 1999. Prospective, randomized, double-blind trial comparing teicoplanin and cefazolin as antibiotic prophylaxis in prosthetic vascular surgery. *European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology* 18:175-8
59. Mukhtar RA, Throckmorton AD, Alvarado MD, Ewing CA, Esserman LJ, et al. 2009. Bacteriologic features of surgical site infections following breast surgery. *American journal of surgery* 198:529-31
60. Tejirian T, DiFronzo LA, Haigh PI. 2006. Antibiotic prophylaxis for preventing wound infection after breast surgery: a systematic review and metaanalysis. *Journal of the American College of Surgeons* 203:729-34
61. Spauwen PH. 2000. [Fifty years of plastic surgery in the Netherlands. IV. Treatment of children with cleft lip and palate]. *Nederlands tijdschrift voor geneeskunde* 144:973-80
62. Pittet B, Montandon D, Pittet D. 2005. Infection in breast implants. *The Lancet infectious diseases* 5:94-106

63. Ashraf M, Biswas J, Gupta S, Alam N. 2009. Determinants of wound infections for breast procedures: assessment of the risk of wound infection posed by an invasive procedure for subsequent operation. *International journal of surgery* 7:543-6
64. Hall JC, Hall JL. 2000. Antibiotic prophylaxis for patients undergoing breast surgery. *The Journal of hospital infection* 46:165-70
65. Tran CL, Langer S, Broderick-Villa G, DiFronzo LA. 2003. Does reoperation predispose to postoperative wound infection in women undergoing operation for breast cancer? *The American surgeon* 69:852-6
66. Cunningham M, Bunn F, Handscomb K. 2006. Prophylactic antibiotics to prevent surgical site infection after breast cancer surgery. *The Cochrane database of systematic reviews*:CD005360
67. Felipe WA, Werneck GL, Santoro-Lopes G. 2007. Surgical site infection among women discharged with a drain in situ after breast cancer surgery. *World journal of surgery* 31:2293-9; discussion 300-1
68. Araco A, Gravante G, Araco F, Delogu D, Cervelli V, Walgenbach K. 2007. Infections of breast implants in aesthetic breast augmentations: a single-center review of 3,002 patients. *Aesthetic plastic surgery* 31:325-9
69. Olsen MA, Lefta M, Dietz JR, Brandt KE, Aft R, et al. 2008. Risk factors for surgical site infection after major breast operation. *Journal of the American College of Surgeons* 207:326-35
70. Ng D, Trivedi PM, Sharma AK, Banerjee D. 2007. Current use of antibiotic prophylaxis in breast surgery: a nationwide survey. *Breast* 16:68-72
71. Edwards JR, Peterson KD, Mu Y, Banerjee S, Allen-Bridson K, et al. 2009. National Healthcare Safety Network (NHSN) report: data summary for 2006 through 2008, issued December 2009. *American journal of infection control* 37:783-805
72. Brahmhatt RD, Huebner M, Scow JS, Harmsen WS, Boughey JC, et al. 2012. National practice patterns in preoperative and postoperative antibiotic prophylaxis in breast procedures requiring drains: survey of the American Society of Breast Surgeons. *Annals of surgical oncology* 19:3205-11
73. Dellinger EP, Gross PA, Barrett TL, Krause PJ, Martone WJ, et al. 1994. Quality standard for antimicrobial prophylaxis in surgical procedures. Infectious Diseases Society of America. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 18:422-7
74. Ahmadi AH, Cohen BE, Shayani P. 2005. A prospective study of antibiotic efficacy in preventing infection in reduction mammoplasty. *Plastic and reconstructive surgery* 116:126-31
75. Hall JC, Willsher PC, Hall JL. 2006. Randomized clinical trial of single-dose antibiotic prophylaxis for non-reconstructive breast surgery. *The British journal of surgery* 93:1342-6
76. Platt R, Zucker JR, Zaleznik DF, Hopkins CC, Dellinger EP, et al. 1993. Perioperative antibiotic prophylaxis and wound infection following breast surgery. *The Journal of antimicrobial chemotherapy* 31 Suppl B:43-8
77. Serletti JM, Davenport MS, Herrera HR, Caldwell EH. 1994. Efficacy of prophylactic antibiotics in reduction mammoplasty. *Annals of plastic surgery* 33:476-80
78. Cabaluna ND, Uy GB, Galicia RM, Cortez SC, Yray MD, Buckley BS. 2013. A randomized, double-blinded placebo-controlled clinical trial of the routine use of preoperative antibiotic prophylaxis in modified radical mastectomy. *World journal of surgery* 37:59-66
79. LeRoy J, Given KS. 1991. Wound infection in breast augmentation: the role of prophylactic perioperative antibiotics. *Aesthetic plastic surgery* 15:303-5
80. Kompatscher P, von Planta A, Spicher I, Seifert B, Vetter S, et al. 2003. Comparison of the incidence and predicted risk of early surgical site infections after breast reduction. *Aesthetic plastic surgery* 27:308-14
81. Bunn F, Jones DJ, Bell-Syer S. 2012. Prophylactic antibiotics to prevent surgical site infection after breast cancer surgery. *The Cochrane database of systematic reviews* 1:CD005360
82. Sajid MS, Hutson K, Akhter N, Kalra L, Rapisarda IF, Bonomi R. 2012. An updated meta-analysis on the effectiveness of preoperative prophylactic antibiotics in patients undergoing breast surgical procedures. *The breast journal* 18:312-7
83. Khan UD. 2010. Breast augmentation, antibiotic prophylaxis, and infection: comparative analysis of 1,628 primary augmentation mammoplasties assessing the role and efficacy of antibiotics prophylaxis duration. *Aesthetic plastic surgery* 34:42-7
84. Mirzabeigi MN, Mericli AF, Ortlip T, Tuma GA, Copit SE, et al. 2012. Evaluating the role of postoperative prophylactic antibiotics in primary and secondary breast augmentation: a retrospective review. *Aesthetic surgery journal / the American Society for Aesthetic Plastic surgery* 32:61-8
85. Liu DZ, Dubbins JA, Louie O, Said HK, Neligan PC, Mathes DW. 2012. Duration of antibiotics after microsurgical breast reconstruction does not change surgical infection rate. *Plastic and reconstructive surgery* 129:362-7

86. Phillips BT, Bishawi M, Dagum AB, Khan SU, Bui DT. 2013. A systematic review of antibiotic use and infection in breast reconstruction: what is the evidence? *Plastic and reconstructive surgery* 131:1-13
87. Throckmorton AD, Boughey JC, Boostrom SY, Holifield AC, Stobbs MM, et al. 2009. Postoperative prophylactic antibiotics and surgical site infection rates in breast surgery patients. *Annals of surgical oncology* 16:2464-9
88. Simmons RL. 1982. Wound infection: a review of diagnosis and treatment. *Infection control : IC* 3:44-51
89. Shea JA, Healey MJ, Berlin JA, Clarke JR, Malet PF, et al. 1996. Mortality and complications associated with laparoscopic cholecystectomy. A meta-analysis. *Annals of surgery* 224:609-20
90. Zacks SL, Sandler RS, Rutledge R, Brown RS, Jr. 2002. A population-based cohort study comparing laparoscopic cholecystectomy and open cholecystectomy. *The American journal of gastroenterology* 97:334-40
91. Varela JE, Wilson SE, Nguyen NT. 2010. Laparoscopic surgery significantly reduces surgical-site infections compared with open surgery. *Surgical endoscopy* 24:270-6
92. Richards C, Edwards J, Culver D, Emori TG, Tolson J, et al. 2003. Does using a laparoscopic approach to cholecystectomy decrease the risk of surgical site infection? *Annals of surgery* 237:358-62
93. Romy S, Eisenring MC, Bettschart V, Petignat C, Francioli P, Troillet N. 2008. Laparoscope use and surgical site infections in digestive surgery. *Annals of surgery* 247:627-32
94. Sanabria A, Dominguez LC, Valdivieso E, Gomez G. 2010. Antibiotic prophylaxis for patients undergoing elective laparoscopic cholecystectomy. *The Cochrane database of systematic reviews*:CD005265
95. Sarli L, Pietra N, Costi R, Grattarola M. 1999. Gallbladder perforation during laparoscopic cholecystectomy. *World journal of surgery* 23:1186-90
96. Chang WT, Lee KT, Chuang SC, Wang SN, Kuo KK, et al. 2006. The impact of prophylactic antibiotics on postoperative infection complication in elective laparoscopic cholecystectomy: a prospective randomized study. *American journal of surgery* 191:721-5
97. Kuthe SA, Kaman L, Verma GR, Singh R. 2006. Evaluation of the role of prophylactic antibiotics in elective laparoscopic cholecystectomy: a prospective randomized trial. *Tropical gastroenterology : official journal of the Digestive Diseases Foundation* 27:54-7
98. Goldfaden A, Birkmeyer JD. 2005. Evidence-based practice in laparoscopic surgery: perioperative care. *Surgical innovation* 12:51-61
99. Lippert H, Gastinger J. 1998. Antimicrobial prophylaxis in laparoscopic and conventional cholecystectomy . Conclusions of a large prospective multicenter quality assurance study in Germany. *Chemotherapy* 44:355-63
100. Choudhary A, Bechtold ML, Puli SR, Othman MO, Roy PK. 2008. Role of prophylactic antibiotics in laparoscopic cholecystectomy: a meta-analysis. *Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract* 12:1847-53; discussion 53
101. Zhou H, Zhang J, Wang Q, Hu Z. 2009. Meta-analysis: Antibiotic prophylaxis in elective laparoscopic cholecystectomy. *Alimentary pharmacology & therapeutics* 29:1086-95
102. Guzman-Valdivia G. 2008. Routine administration of antibiotics to patients suffering accidental gallbladder perforation during laparoscopic cholecystectomy is not necessary. *Surgical laparoscopy, endoscopy & percutaneous techniques* 18:547-50
103. McGuckin M, Shea JA, Schwartz JS. 1999. Infection and antimicrobial use in laparoscopic cholecystectomy. *Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America* 20:624-6
104. Kacelnik O, Alberg T, Mjaland O, Eriksen H, Skjeldestad FE. 2013. Guidelines for antibiotic prophylaxis of cholecystectomies in Norwegian hospitals. *Surgical infections* 14:188-91
105. Catarci M, Mancini S, Gentileschi P, Camplone C, Sileri P, Grassi GB. 2004. Antibiotic prophylaxis in elective laparoscopic cholecystectomy. Lack of need or lack of evidence? *Surgical endoscopy* 18:638-41
106. SNLG (Sistema Nazionale Linee Guida). Antibiotico profilassi perioperatoria nell'adulto. 2008
107. Gordon HR, Phelps D, Blanchard K. 1979. Prophylactic cesarean section antibiotics: maternal and neonatal morbidity before or after cord clamping. *Obstetrics and gynecology* 53:151-6
108. 1999. ASHP Therapeutic Guidelines on Antimicrobial Prophylaxis in Surgery. American Society of Health-System Pharmacists. *American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists* 56:1839-88
109. SIGN - Scottish Intercollegiate Guidelines Network. Antibiotic prophylaxis in surgery. July 2000
110. American College of Obstetricians and Gynecologists. ACOG practice bulletin number 47, October 2003: Prophylactic antibiotics in labor and delivery. *Obstet Gynecol* 2003;102(4):875-82.
111. Kozyrskij AL, Ernst P, Becker AB. 2007. Increased risk of childhood asthma from antibiotic use in early life. *Chest* 131:1753-9

112. Caesarean section. NICE clinical guideline 132 (issued november 2011, last modified august 2012)
113. 2010. Committee opinion no. 465: antimicrobial prophylaxis for cesarean delivery: timing of administration. *Obstetrics and gynecology* 116:791-2
114. Costantine MM, Rahman M, Ghulmiyah L, Byers BD, Longo M, et al. 2008. Timing of perioperative antibiotics for cesarean delivery: a metaanalysis. *American journal of obstetrics and gynecology* 199:301 e1-6
115. Baaqeel H, Baaqeel R. 2013. Timing of administration of prophylactic antibiotics for caesarean section: a systematic review and meta-analysis. *BJOG : an international journal of obstetrics and gynaecology* 120:661-9
116. Heesen M, Klohr S, Rossaint R, Allegeaert K, Deprest J, et al. 2013. Concerning the timing of antibiotic administration in women undergoing caesarean section: a systematic review and meta-analysis. *BMJ open* 3
117. Kaimal AJ, Zlatnik MG, Cheng YW, Thiet MP, Connatty E, et al. 2008. Effect of a change in policy regarding the timing of prophylactic antibiotics on the rate of postcesarean delivery surgical-site infections. *American journal of obstetrics and gynecology* 199:310 e1-5
118. Owens SM, Brozanski BS, Meyn LA, Wiesenfeld HC. 2009. Antimicrobial prophylaxis for cesarean delivery before skin incision. *Obstetrics and gynecology* 114:573-9
119. Young BC, Hacker MR, Dodge LE, Golen TH. 2012. Timing of antibiotic administration and infectious morbidity following cesarean delivery: incorporating policy change into workflow. *Archives of gynecology and obstetrics* 285:1219-24
120. Brown J, Thompson M, Sinnya S, Jeffery A, de Costa C, et al. 2013. Pre-incision antibiotic prophylaxis reduces the incidence of post-caesarean surgical site infection. *The Journal of hospital infection* 83:68-70
121. Macones GA, Cleary KL, Parry S, Stamilio DM, Cahill AG, et al. 2012. The timing of antibiotics at cesarean: a randomized controlled trial. *American journal of perinatology* 29:273-6
122. Francis C, Mumford M, Strand ML, Moore ES, Strand EA. 2013. Timing of prophylactic antibiotic at cesarean section: a double-blinded, randomized trial. *Journal of perinatology : official journal of the California Perinatal Association* 33:759-62
123. Kalaranjini S, Veena P, Rani R. 2013. Comparison of administration of single dose ceftriaxone for elective caesarean section before skin incision and after cord clamping in preventing post-operative infectious morbidity. *Archives of gynecology and obstetrics* 288:1263-8
124. Tita AT, Rouse DJ, Blackwell S, Saade GR, Spong CY, Andrews WW. 2009. Emerging concepts in antibiotic prophylaxis for cesarean delivery: a systematic review. *Obstetrics and gynecology* 113:675-82
125. Lamont RF, Sobel JD, Kusanovic JP, Vaisbuch E, Mazaki-Tovi S, et al. 2011. Current debate on the use of antibiotic prophylaxis for caesarean section. *BJOG : an international journal of obstetrics and gynaecology* 118:193-201
126. Sun J, Ding M, Liu J, Li Y, Sun X, et al. 2013. Prophylactic administration of cefazolin prior to skin incision versus antibiotics at cord clamping in preventing postcesarean infectious morbidity: a systematic review and meta-analysis of randomized controlled trials. *Gynecologic and obstetric investigation* 75:175-8
127. Van Schalkwyk J, Van Eyk N; Society of Obstetricians and Gynaecologists of Canada Infectious Diseases Committee. Antibiotic prophylaxis in obstetric procedures. *J Obstet Gynaecol Can* 2010;32(9):878-92
128. Tenke P, Koves B, Nagy K, Hultgren SJ, Mendling W, et al. 2012. Update on biofilm infections in the urinary tract. *World journal of urology* 30:51-7
129. Wolf JS, Jr., Bennett CJ, Dmochowski RR, Hollenbeck BK, Pearle MS, et al. 2008. Best practice policy statement on urologic surgery antimicrobial prophylaxis. *The Journal of urology* 179:1379-90
130. Bjerklund Johansen TE, Cek M, Naber K, Stratchounski L, Svendsen MV, et al. 2007. Prevalence of hospital-acquired urinary tract infections in urology departments. *European urology* 51:1100-11; discussion 12
131. Cox CE. 1989. Comparison of intravenous ciprofloxacin and intravenous cefotaxime for antimicrobial prophylaxis in transurethral surgery. *The American journal of medicine* 87:252S-4S
132. Cam K, Kayikci A, Akman Y, Erol A. 2008. Prospective assessment of the efficacy of single dose versus traditional 3-day antimicrobial prophylaxis in 12-core transrectal prostate biopsy. *International journal of urology : official journal of the Japanese Urological Association* 15:997-1001
133. Aron M, Rajeev TP, Gupta NP. 2000. Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study. *BJU international* 85:682-5
134. Kapoor DA, Klimberg IW, Malek GH, Wegenke JD, Cox CE, et al. 1998. Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy. *Urology* 52:552-8
135. Wagenlehner FM, Wagenlehner C, Schinzel S, Naber KG, Working Group "Urological Infections" of German Society of U. 2005. Prospective, randomized, multicentric, open, comparative study on the efficacy of a

- prophylactic single dose of 500 mg levofloxacin versus 1920 mg trimethoprim/sulfamethoxazole versus a control group in patients undergoing TUR of the prostate. *European urology* 47:549-56
136. Brewster SF, MacGowan AP, Gingell JC. 1995. Antimicrobial prophylaxis for transrectal prostatic biopsy: a prospective randomized trial of cefuroxime versus piperacillin/tazobactam. *British journal of urology* 76:351-4
 137. Togo Y, Tanaka S, Kanematsu A, Ogawa O, Miyazato M, et al. 2013. Antimicrobial prophylaxis to prevent perioperative infection in urological surgery: a multicenter study. *Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy* 19:1093-101
 138. Turano A. 1992. New clinical data on the prophylaxis of infections in abdominal, gynecologic, and urologic surgery. Multicenter Study Group. *American journal of surgery* 164:16S-20S
 139. Kartal ED, Yenilmez A, Kiremitci A, Meric H, Kale M, Usluer G. 2006. Effectiveness of ciprofloxacin prophylaxis in preventing bacteriuria caused by urodynamic study: a blind, randomized study of 192 patients. *Urology* 67:1149-53
 140. Platt R, Zucker JR, Zaleznik DF, Hopkins CC, Dellinger EP, et al. 1992. Prophylaxis against wound infection following herniorrhaphy or breast surgery. *The Journal of infectious diseases* 166:556-60
 141. Platt R, Zaleznik DF, Hopkins CC, Dellinger EP, Karchmer AW, et al. 1990. Perioperative antibiotic prophylaxis for herniorrhaphy and breast surgery. *The New England journal of medicine* 322:153-60
 142. Troy MG, Dong QS, Dobrin PB, Hecht D. 1996. Do topical antibiotics provide improved prophylaxis against bacterial growth in the presence of polypropylene mesh? *American journal of surgery* 171:391-3
 143. EU Hernia Trialists Collaboration. Mesh compared with non-mesh methods of open groin hernia repair: systematic review of randomized controlled trials. *Br J Surg* 2000;87(7):854-9.
 144. Condon RE, Wittmann DH. 1991. The use of antibiotics in general surgery. *Current problems in surgery* 28:801-949
 145. Page CP, Bohnen JM, Fletcher JR, McManus AT, Solomkin JS, Wittmann DH. 1993. Antimicrobial prophylaxis for surgical wounds. Guidelines for clinical care. *Archives of surgery* 128:79-88
 146. Cainzos M, Lozano F, Balibrea JL, et al. La infección postoperatoria: estudio multicéntrico, prospectivo y controlado. *Cir Esp* 1990;48(5):481-90.
 147. Holmes J, Readman R. 1994. A study of wound infections following inguinal hernia repair. *The Journal of hospital infection* 28:153-6
 148. Bailey IS, Karran SE, Toyn K, Brough P, Ranaboldo C, Karran SJ. 1992. Community surveillance of complications after hernia surgery. *Bmj* 304:469-71
 149. Goodney PP, Birkmeyer CM, Birkmeyer JD. 2002. Short-term outcomes of laparoscopic and open ventral hernia repair: a meta-analysis. *Archives of surgery* 137:1161-5
 150. Forbes SS, Eskicioglu C, McLeod RS, Okrainec A. 2009. Meta-analysis of randomized controlled trials comparing open and laparoscopic ventral and incisional hernia repair with mesh. *The British journal of surgery* 96:851-8
 151. Itani KM, Hur K, Kim LT, Anthony T, Berger DH, et al. 2010. Comparison of laparoscopic and open repair with mesh for the treatment of ventral incisional hernia: a randomized trial. *Archives of surgery* 145:322-8; discussion 8
 152. Codina C, Trilla A, Riera N, Tuset M, Carne X, et al. 1999. Perioperative antibiotic prophylaxis in Spanish hospitals: results of a questionnaire survey. Hospital Pharmacy Antimicrobial Prophylaxis Study Group. *Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America* 20:436-9
 153. Aiken AM, Haddow JB, Symons NR, Kaptanis S, Katz-Summercorn AC, et al. 2013. Use of antibiotic prophylaxis in elective inguinal hernia repair in adults in London and south-east England: a cross-sectional survey. *Hernia : the journal of hernias and abdominal wall surgery* 17:657-64
 154. Burton RC. 1973. Postoperative wound infection in colonic and rectal surgery. *The British journal of surgery* 60:363-5
 155. Gorbach SL, Condon RE, Conte JE, Jr., Kaiser AB, Ledger WJ, Nichols RL. 1992. Evaluation of new anti-infective drugs for surgical prophylaxis. Infectious Diseases Society of America and the Food and Drug Administration. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 15 Suppl 1:S313-38
 156. Song F, Glenny AM. 1998. Antimicrobial prophylaxis in colorectal surgery: a systematic review of randomized controlled trials. *The British journal of surgery* 85:1232-41
 157. Baum ML, Anish DS, Chalmers TC, Sacks HS, Smith H, Jr., Fagerstrom RM. 1981. A survey of clinical trials of antibiotic prophylaxis in colon surgery: evidence against further use of no-treatment controls. *The New England journal of medicine* 305:795-9

158. Coppa GF, Eng K, Gouge TH, Ranson JH, Localio SA. 1983. Parenteral and oral antibiotics in elective colon and rectal surgery. A prospective, randomized trial. *American journal of surgery* 145:62-5
159. Glenny AM, Song F. 1999. Antimicrobial prophylaxis in colorectal surgery. *Quality in health care : QHC* 8:132-6
160. Konishi T, Watanabe T, Kishimoto J, Nagawa H. 2006. Elective colon and rectal surgery differ in risk factors for wound infection: results of prospective surveillance. *Annals of surgery* 244:758-63
161. Nakamura T, Mitomi H, Ihara A, Onozato W, Sato T, et al. 2008. Risk factors for wound infection after surgery for colorectal cancer. *World journal of surgery* 32:1138-41
162. Poon JT, Law WL, Wong IW, Ching PT, Wong LM, et al. 2009. Impact of laparoscopic colorectal resection on surgical site infection. *Annals of surgery* 249:77-81
163. Kiran RP, Khoury W, Church JM, Lavery IC, Fazio VW, Remzi FH. 2010. Colorectal cancer complicating inflammatory bowel disease: similarities and differences between Crohn's and ulcerative colitis based on three decades of experience. *Annals of surgery* 252:330-5
164. Senagore AJ, Stulberg JJ, Byrnes J, Delaney CP. 2009. A national comparison of laparoscopic vs. open colectomy using the National Surgical Quality Improvement Project data. *Diseases of the colon and rectum* 52:183-6
165. KISS Hospital Infection Surveillance System (Krankenhaus-Infektions-Surveillance-System). OP-KISS Reference Data, 2005-2009. Nationales referenzzentrum für surveillance von nosokomialen infektionen, 2010. URL (ultimo accesso 28/9/2013): <http://www.nrz-hygiene.de/en/surveillance/hospital-infection-surveillance-system/op-kiss>
166. Perennec-Olivier M, Jarno P. Surveillance des infections du site opératoire. Saint-Maurice, Institut de Veille Sanitaire; Réseau ISO-Raisin, Surveillance des infections du site opératoire. France, 2011. URL (ultimo accesso 28/9/2013): <http://www.invs.sante.fr/Publications-et-outils/Rapports-et-syntheses/Maladies-infectieuses/2012/Surveillance-des-infections-du-site-operatoire-France-2011>
167. Marchi M, Pan A, Parenti M, Moro ML. Sistema Nazionale di Sorveglianza delle Infezioni del Sito Chirurgico. Sorveglianza delle infezioni del sito chirurgico in Italia (2011-2012). Settembre 2013. URL (ultimo accesso 28/9/2013)
168. Poth EJ. 1953. Intestinal antisepsis in surgery. *Journal of the American Medical Association* 153:1516-21
169. Nichols RL, Condon RE. 1971. Preoperative preparation of the colon. *Surgery, gynecology & obstetrics* 132:323-37
170. Washington JA, 2nd, Dearing WH, Judd ES, Elveback LR. 1974. Effect of preoperative antibiotic regimen on development of infection after intestinal surgery: Prospective, randomized, double-blind study. *Annals of surgery* 180:567-72
171. Goldring J, McNaught W, Scott A, Gillespie G. 1975. Prophylactic oral antimicrobial agents in elective colonic surgery. A controlled trial. *Lancet* 2:997-1000
172. Clarke JS, Condon RE, Bartlett JG, Gorbach SL, Nichols RL, Ochi S. 1977. Preoperative oral antibiotics reduce septic complications of colon operations: results of prospective, randomized, double-blind clinical study. *Annals of surgery* 186:251-9
173. Bartlett JG, Condon RE, Gorbach SL, Clarke JS, Nichols RL, Ochi S. 1978. Veterans Administration Cooperative Study on Bowel Preparation for Elective Colorectal Operations: impact of oral antibiotic regimen on colonic flora, wound irrigation cultures and bacteriology of septic complications. *Annals of surgery* 188:249-54
174. Wapnick S, Guinto R, Reizis I, LeVein HH. 1979. Reduction of postoperative infection in elective colon surgery with preoperative administration of kanamycin and erythromycin. *Surgery* 85:317-21
175. Jung B, Matthiessen P, Smedh K, Nilsson E, Ransjo U, Pahlman L. 2010. Mechanical bowel preparation does not affect the intramucosal bacterial colony count. *International journal of colorectal disease* 25:439-42
176. Smith MB, Goradia VK, Holmes JW, McCluggage SG, Smith JW, Nichols RL. 1990. Suppression of the human mucosal-related colonic microflora with prophylactic parenteral and/or oral antibiotics. *World journal of surgery* 14:636-41
177. Cannon JA, Altom LK, Deierhoi RJ, Morris M, Richman JS, et al. 2012. Preoperative oral antibiotics reduce surgical site infection following elective colorectal resections. *Diseases of the colon and rectum* 55:1160-6
178. Santos JC, Jr., Batista J, Sirimarco MT, Guimaraes AS, Levy CE. 1994. Prospective randomized trial of mechanical bowel preparation in patients undergoing elective colorectal surgery. *The British journal of surgery* 81:1673-6
179. Bucher P, Mermillod B, Gervaz P, Morel P. 2004. Mechanical bowel preparation for elective colorectal surgery: a meta-analysis. *Archives of surgery* 139:1359-64; discussion 65
180. Slim K, Flamein R, Brugere C. La préparation colique pré-opératoire est-elle utile? *J Chir* 2004;141(5):285-92
181. Nichols RL, Choe EU, Weldon CB. 2005. Mechanical and antibacterial bowel preparation in colon and rectal surgery. *Chemotherapy* 51 Suppl 1:115-21

182. Ram E, Sherman Y, Weil R, Vishne T, Kravarusic D, Dreznik Z. 2005. Is mechanical bowel preparation mandatory for elective colon surgery? A prospective randomized study. *Archives of surgery* 140:285-8
183. Contant CM, Hop WC, van't Sant HP, Oostvogel HJ, Smeets HJ, et al. 2007. Mechanical bowel preparation for elective colorectal surgery: a multicentre randomised trial. *Lancet* 370:2112-7
184. Jung B, Pahlman L, Nystrom PO, Nilsson E, Mechanical Bowel Preparation Study G. 2007. Multicentre randomized clinical trial of mechanical bowel preparation in elective colonic resection. *The British journal of surgery* 94:689-95
185. Slim K, Vicaut E, Launay-Savary MV, Contant C, Chipponi J. 2009. Updated systematic review and meta-analysis of randomized clinical trials on the role of mechanical bowel preparation before colorectal surgery. *Annals of surgery* 249:203-9
186. Guinier D, Manton GA, Alves A, Kwiatkowski F, Slim K, et al. 2007. Risk factors of unplanned readmission after colorectal surgery: a prospective, multicenter study. *Diseases of the colon and rectum* 50:1316-23
187. Eskicioglu C, Forbes SS, Fenech DS, McLeod RS, Best Practice in General Surgery C. 2010. Preoperative bowel preparation for patients undergoing elective colorectal surgery: a clinical practice guideline endorsed by the Canadian Society of Colon and Rectal Surgeons. *Canadian journal of surgery. Journal canadien de chirurgie* 53:385-95
188. Zhu QD, Zhang QY, Zeng QQ, Yu ZP, Tao CL, Yang WJ. 2010. Efficacy of mechanical bowel preparation with polyethylene glycol in prevention of postoperative complications in elective colorectal surgery: a meta-analysis. *International journal of colorectal disease* 25:267-75
189. Van't Sant HP, Weidema WF, Hop WC, Oostvogel HJ, Contant CM. 2010. The influence of mechanical bowel preparation in elective lower colorectal surgery. *Annals of surgery* 251:59-63
190. Guenaga KF, Matos D, Wille-Jorgensen P. 2011. Mechanical bowel preparation for elective colorectal surgery. *The Cochrane database of systematic reviews*:CD001544
191. Wren SM, Ahmed N, Jamal A, Safadi BY. 2005. Preoperative oral antibiotics in colorectal surgery increase the rate of *Clostridium difficile* colitis. *Archives of surgery* 140:752-6
192. Krapohl GL, Phillips LR, Campbell DA, Jr., Hendren S, Banerjee M, et al. 2011. Bowel preparation for colectomy and risk of *Clostridium difficile* infection. *Diseases of the colon and rectum* 54:810-7
193. Polk HC, Jr., Lopez-Mayor JF. 1969. Postoperative wound infection: a prospective study of determinant factors and prevention. *Surgery* 66:97-103
194. Condon RE, Bartlett JG, Nichols RL, Schulte WJ, Gorbach SL, Ochi S. 1979. Preoperative prophylactic cephalothin fails to control septic complications of colorectal operations: results of controlled clinical trial. A Veterans Administration cooperative study. *American journal of surgery* 137:68-74
195. Lewis RT, Allan CM, Goodall RG, Marien B, Park M, et al. 1983. Are first-generation cephalosporins effective for antibiotic prophylaxis in elective surgery of the colon? *Canadian journal of surgery. Journal canadien de chirurgie* 26:504-7
196. Keighley MR, Arabi Y, Alexander-Williams J, Youngs D, Burdon DW. 1979. Comparison between systemic and oral antimicrobial prophylaxis in colorectal surgery. *Lancet* 1:894-7
197. Dion YM, Richards GK, Prentis JJ, Hinchey EJ. 1980. The influence of oral versus parenteral preoperative metronidazole on sepsis following colon surgery. *Annals of surgery* 192:221-6
198. Englesbe MJ, Brooks L, Kubus J, Luchtefeld M, Lynch J, et al. 2010. A statewide assessment of surgical site infection following colectomy: the role of oral antibiotics. *Annals of surgery* 252:514-9; discussion 9-20
199. Nelson RL, Glenny AM, Song F. 2009. Antimicrobial prophylaxis for colorectal surgery. *The Cochrane database of systematic reviews*:CD001181
200. Eagye KJ, Nicolau DP. 2011. Selection of prophylactic antimicrobial agent may affect incidence of infection in small bowel and colorectal surgery. *Surgical infections* 12:451-7
201. Ho VP, Barie PS, Stein SL, Trencheva K, Milsom JW, et al. 2011. Antibiotic regimen and the timing of prophylaxis are important for reducing surgical site infection after elective abdominal colorectal surgery. *Surgical infections* 12:255-60
202. Hendren S, Fritze D, Banerjee M, Kubus J, Cleary RK, et al. 2013. Antibiotic choice is independently associated with risk of surgical site infection after colectomy: a population-based cohort study. *Annals of surgery* 257:469-75
203. Tang R, Chen HH, Wang YL, Changchien CR, Chen JS, et al. 2001. Risk factors for surgical site infection after elective resection of the colon and rectum: a single-center prospective study of 2,809 consecutive patients. *Annals of surgery* 234:181-9

Table 1. Pathogens commonly associated with different surgical procedures.

Type of surgery	Common pathogens
Placement of graft, prosthesis or implant	<i>Staphylococcus aureus</i> ; CoNS
Cardiac	<i>S. aureus</i> ; CoNS
Neurosurgery	<i>S. aureus</i> ; CoNS
Breast	<i>S. aureus</i> ; CoNS
Ophthalmic	<i>S. aureus</i> ; CoNS; streptococci; Gram-negative bacilli
Orthopaedic	<i>S. aureus</i> ; CoNS; Gram-negative bacilli
Vascular	<i>S. aureus</i> ; CoNS
Appendectomy	Gram-negative bacilli; anaerobes
Biliary tract	Gram-negative bacilli; anaerobes
Colorectal	Gram-negative bacilli; Enterococcus spp.; anaerobes
Gastroduodenal	Gram-negative bacilli; streptococci; oropharyngeal anaerobes (e.g. peptostreptococci)
Obstetric and gynaecological	Gram-negative bacilli; enterococci; Group B streptococci; anaerobes

CoNS: coagulase-negative staphylococci

Table 2. Recommended dosage for commonly used antibiotics in surgical prophylaxis

Antimicrobials	Recommended Dose for Adults
Ampicillin-sulbactam	3 g
Ampicillin	2 g
Aztreonam	2 g
Cefazolin	2g; 3 g for patients with body weight > 120 kg
Cefuroxime	1, 5 g
Cefotaxime	1 g
Cefoxitin	2 g
Cefotetan	2 g
Ceftriaxone	2 g
Ciprofloxacin	400 mg
Clindamycin	900 mg
Ertapenem	1 gr
Gentamicin	5 mg/ Kg (single dose given preoperatively)
Levofloxacin	500 mg
Metronidazole	500 mg
Moxifloxacin	400 mg
Piperacillin-tazobactam	3,375 g (4,5 g in Italy)
Vancomycin	15 mg/kg

Table 3. Recommended agents for different types of surgical procedure

Type of procedure	Recommended agents	Alternative agents in patients with B-lactams allergy
Cardiac -Coronary artery by-pass -Cardiac device insertion procedures -Ventricular assist device	Cefazolin; Cefuroxime	Clindamycin; Vancomycin
Thoracic -non cardiac procedures - video-assisted thoracoscopic surgery	Cefazolin; Ampicillin-sulbactam	Clindamycin; Vancomycin
Gastrointestinal -involving entry in the lumen -without entry in the lumen	Cefazolin	Clindamycin or vancomycin + aminoglycoside or aztreonam or fluoroquinolone
Biliary tract -	Cefazolin; cefotetan; cefoxitin; ceftriaxone; amp/sulbactam	Clindamycin+ aminoglycoside or aztreonam or fluoroquinolone; metronidazole+ aminoglycoside or fluoroquinolones
Appendectomy	Cefoxitin; cefotetan; cefazolin+metronidazole	Clindamycin+ aminoglycoside or aztreonam or fluoroquinolone; metronidazole+ aminoglycoside or fluoroquinolones
Hernia repair (hernioplasty and herniorrhaphy)	Cefazolin	Clindamycin Vancomycin
Colorectal	Cefazolin/ceftriaxone + metronidazole; cefotetan; amp/sulbact; cefoxitin	Clindamycin+ aminoglycoside or aztreonam or fluoroquinolone; metronidazole+ aminoglycoside or

		fluoroquinolones
Neurosurgery	Cefazolin	Clindamycin vancomycin
Cesarian	cefazolin	Clindamycin+ aminoglycoside
Orthopedic Spinal procedures with or without instrumentation	cefazolin	Clindamycin Vancomycin

Table 4. Evidence for antimicrobial recommended regimens in the surgical procedures described

Type of procedure	Recommended agents	Reference
Ocular surgery	cephalosporins, vancomycin, aminoglycosides, quinolones	[35-42]
Neurosurgery	cephalosporins	[46-49]
Vascular surgery	cefazolin	[54-57]
Breast Surgery	cefalosporins	[76-82]
Cesarian section	Cefazolin (\pm metronidazole)	[165-167]
Urological surgery	cephalosporins, fluoroquinolones, aminoglycosides, nitrofurantoin and trimethoprim-sulfamethaxazole	[131-133]
Hernia repair	cefazolin	[108]
Colorectal surgery	Cefazolin + metronidazole, cefoxitin, cefotetan, ampicillin-sulbactam, ceftriaxone + metronidazole, ertapenem (\pm oral antibiotics)	[108]